Tibco Software has announced that the Walter and Eliza Hall Institute of Medical Research will employ the Tibco Spotfire analytics platform to advance its drug discovery process.
The platform will reduce the time the medical research institute takes to filter and analyse millions of laboratory test results by more than 65 per cent.
Life-sciences organisations such as the Walter and Eliza Hall Institute of Medical Research (WEHI) face significant pressure to quickly identify and test potential novel drug therapies.
To identify these molecules candidates, WEHI scientists test a bank of more than 350,000 compounds on a daily basis.
With Tibco Spotfire's interactive and visual interface, WEHI researchers will be able to quickly and easily spot trends, outliers, and errors in large data volumes of molecular compounds in assay results, and explore real-time hypotheses in various conditions.
With the Tibco Spotfire analytics platform, WEHI is also able to leverage Spotfire's integration with IDBS's Activitybase drug discovery informatics database.
This will enable it to incorporate data from both molecular and cellular screening campaigns to easily identify and exclude problematic trends in data and candidates, saving time for better and smarter decision-making; and quickly identify candidates and results for follow-up to speed up the overall drug discovery process.
The implementation of Tibco Spotfire has also assisted WEHI in its public-private partnership role with the Cancer Therapeutics Co-operative Research Centre (CTx CRC).
CTx CRC members use Spotfire analytics to analyse the data that their laboratory systems produce, delivering similar efficiency improvements on a more specific set of candidate molecules that can be analysed in-depth by other affiliated researchers.
